This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Parkinson Study Group

Arch Neurol. 1989;46(10):1052-1060.

Abstract
• DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) is a placebo-controlled clinical trial designed to test the hypothesis that long-term treatment of patients with early Parkinson's disease with deprenyl 10 mg/d and/or tocopherol (vitamin E) 2000 IU/d will extend the time until disability requires therapy with levodopa (primary end point). At 28 US and Canadian sites, 800 eligible patients in the early stages of untreated Parkinson's disease were enrolled in DATATOP and randomized to (1) active deprenyl, (2) active tocopherol, (3) active deprenyl and tocopherol, or (4) placebo treatments. Subjects are being evaluated systematically at regular intervals over 2 years to determine if and when the primary end point of disability is attained. At baseline evaluation, our cohort represented minimally disabled patients with Parkinson's disease who did not require symptomatic anti-Parkinson's disease medications. Despite an almost 2:1 representation of male-female subjects, no selection biases were identified that might confound the primary end-point analysis. This large DATATOP cohort is expected to provide a high likelihood (power) for detecting significant treatment effects, if indeed they exist.

Footnotes
Accepted for publication June 9, 1989.

Supported by the National Institute of Neurological Diseases and Stroke, Bethesda, Md.

Reprint requests to Box 673, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642 (Dr Shoulson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort
Uc et al.
Neurology 2009;73:1469-1477.
ABSTRACT | FULL TEXT  

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio et al.
Arch Neurol 2009;0:2009.247-9.
ABSTRACT | FULL TEXT  

The Relationships Between the Unified Parkinson's Disease Rating Scale and Lower Extremity Functional Performance in Persons With Early-Stage Parkinson's Disease
Song et al.
Neurorehabil Neural Repair 2009;23:657-661.
ABSTRACT  

Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Parashos et al.
Arch Neurol 2009;66:1099-1104.
ABSTRACT | FULL TEXT  

Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial
Weaver et al.
JAMA 2009;301:63-73.
ABSTRACT | FULL TEXT  

Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure
Schiess and Oh
Arch Neurol 2008;65:698-699.
FULL TEXT  

Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Schwarzschild et al.
Arch Neurol 2008;65:716-723.
ABSTRACT | FULL TEXT  

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators
Neurology 2007;69:1480-1490.
ABSTRACT | FULL TEXT  

Clinical trials aimed at detecting neuroprotection in Parkinson's disease
Hauser and Zesiewicz
Neurology 2006;66:S58-S68.
ABSTRACT | FULL TEXT  

Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs
Tilley et al.
Neurology 2006;66:628-633.
ABSTRACT | FULL TEXT  

Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort
Marras et al.
Neurology 2005;64:87-93.
ABSTRACT | FULL TEXT  

A novel formulation of selegiline for the treatment of Parkinson's disease
Tetrud and Koller
Neurology 2004;63:S2-S6.
FULL TEXT  

Clinical trials of neuroprotection for Parkinson's disease
LeWitt
Neurology 2004;63:S23-S31.
FULL TEXT  

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
Ives et al.
BMJ 2004;329:593.
ABSTRACT | FULL TEXT  

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial
The Parkinson Study Group
Arch Neurol 2004;61:1044-1053.
ABSTRACT | FULL TEXT  

Orthostatic Hypotension in De Novo Parkinson Disease
Bonuccelli et al.
Arch Neurol 2003;60:1400-1404.
ABSTRACT | FULL TEXT  

A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
Parkinson Study Group
Arch Neurol 2002;59:1937-1943.
ABSTRACT | FULL TEXT  

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics
Kompoliti et al.
Neurology 2002;58:1418-1422.
ABSTRACT | FULL TEXT  

Freezing of gait in PD: Prospective assessment in the DATATOP cohort
Giladi et al.
Neurology 2001;56:1712-1721.
ABSTRACT | FULL TEXT  

Welding-related parkinsonism: Clinical features, treatment, and pathophysiology
Racette et al.
Neurology 2001;56:8-13.
ABSTRACT | FULL TEXT  

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group
JAMA 2000;284:1931-1938.
ABSTRACT | FULL TEXT  

The Evolution of Diagnosis in Early Parkinson Disease
Jankovic et al.
Arch Neurol 2000;57:369-372.
ABSTRACT | FULL TEXT  

High doses of vitamin E in the treatment of disorders of the central nervous system in the aged
Vatassery et al.
Am. J. Clin. Nutr. 1999;70:793-801.
ABSTRACT | FULL TEXT  

Clinical and quantitative pathologic correlates of dementia with Lewy bodies
Gomez-Tortosa et al.
Neurology 1999;53:1284-1284.
ABSTRACT | FULL TEXT  

Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias
Hershey et al.
Proc. Natl. Acad. Sci. USA 1998;95:12016-12021.
ABSTRACT | FULL TEXT  

Dietary Antioxidants and Parkinson Disease: The Rotterdam Study
de Rijk et al.
Arch Neurol 1997;54:762-765.
ABSTRACT  

Parkinson disease: A new link between monoamine oxidase and mitochondrial electron flow
Cohen et al.
Proc. Natl. Acad. Sci. USA 1997;94:4890-4894.
ABSTRACT | FULL TEXT  

Drugs for Parkinson's disease reviewed
DTB 1995;33:49-52.
ABSTRACT | FULL TEXT  

Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease
McDermott et al.
Arch Neurol 1995;52:565-570.
ABSTRACT  

Cerebrospinal Fluid Homovanillic Acid in the DATATOP Study on Parkinson's Disease
Parkinson Study Group
Arch Neurol 1995;52:237-245.
ABSTRACT  

High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland et al.
Arch Gen Psychiatry 1994;51:607-615.
ABSTRACT  

Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group
NEJM 1993;328:176-183.
ABSTRACT | FULL TEXT  

Early Therapy for Parkinson's Disease-Reply
Elizan et al.
Arch Neurol 1991;48:1009-1010.
ABSTRACT  

Neurology
Joynt
JAMA 1990;263:2660-2661.
ABSTRACT